Main Article Content
Abstract
This article studies the effectiveness of the drug "Cretamine" against neuropsychological and neurosensory disorders. As part of a clinical study, a positive effect of the drug on the cognitive, emotional and sensory systems was revealed in 80 patients. The results of the study support the complex neuroprotective and metabolic activity of "Cretamine".
Keywords
Article Details
References
- 1. World Health Organization. Mental health action plan 2013-2020 . Geneva: WHO, 2013.
- 2. Patel V. et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. The Lancet , 2016; 387(10028): 1672–1685.
- 3. Gusev EI, Skvortsova VI Neurology . Moscow: GEOTAR-Media, 2021.
- 4. Yakovlev VN Neuropsychological syndromes and mental therapy . St. Petersburg: ELBI-SPb, 2020.
- 5. Gerasimova ME Modern pharmacological approaches to the correction of cognitive impairments. Bulletin of Experimental Biology and Medicine , 2019; 168(9): 102–106.
- 6. Lishman WA Organic Psychiatry: The Psychological Consequences of Cerebral Disorder . Oxford: Wiley-Blackwell, 2017.
- 7. Yuldashev UU et al. The role of adaptogenic therapy in the management of stress-related autonomic dysfunctions. Uzbek Medical Journal , 2020; 6: 45–48.
- 8. Zohidov KK Neuroendocrine regulation and psychovegetative syndromes . Tashkent: TMA, 2021.
- 9. Kilichev SA, Abdurakhmonov IR Clinical and immunometabolic efficacy of "Kretamin" in patients with neurodegenerative syndromes. Neurology and Psychiatry , 2023; 2(5): 38–44.
- 10. Azizova GA Antioxidant protection in neurodegeneration: pharmacological correction strategies. Modern Problems of Science and Education , 2021; 1: 56–59.
- 11. Cummings JL, Mega MS Neuropsychiatry and Behavioral Neuroscience . Oxford University Press, 2018.
- 12. Abdurakhimova NK Application of metabolically active preparations in complex treatment of cerebral atherosclerosis. Journal of Clinical Pharmacology , 2022; 3: 19–23.
- 13. Jumaeva NS Use of combined adaptogenic complexes in psychosomatic dysfunctions. Medical Science and Innovation , 2023; 7(4): 71–74.
- 14. Karimov BR The use of creatine in cerebral circulation disorders. Innovations in Medicine , 2024; 2: 27–32.
- 15. Bechtereva NP Brain and psyche: neurophysiological research . St. Petersburg: Nauka, 2019.
- 16. Khoshimov RS Clinic of Nervous Diseases and Pharmacotherapy . Tashkent: Medicine, 2022.
- 17. WHO. Depression and Other Common Mental Disorders. Global Health Estimates. Geneva, 2017.
- 18. Azizova MM Antistress effects of metabolic agents in experimental neurosis. Central Asian Medical Journal , 2022; 5: 82–85.
- 19. Sarimsakov MA Bioregulators and their psychotropic effects . Tashkent: FAN, 2023.
References
1. World Health Organization. Mental health action plan 2013-2020 . Geneva: WHO, 2013.
2. Patel V. et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. The Lancet , 2016; 387(10028): 1672–1685.
3. Gusev EI, Skvortsova VI Neurology . Moscow: GEOTAR-Media, 2021.
4. Yakovlev VN Neuropsychological syndromes and mental therapy . St. Petersburg: ELBI-SPb, 2020.
5. Gerasimova ME Modern pharmacological approaches to the correction of cognitive impairments. Bulletin of Experimental Biology and Medicine , 2019; 168(9): 102–106.
6. Lishman WA Organic Psychiatry: The Psychological Consequences of Cerebral Disorder . Oxford: Wiley-Blackwell, 2017.
7. Yuldashev UU et al. The role of adaptogenic therapy in the management of stress-related autonomic dysfunctions. Uzbek Medical Journal , 2020; 6: 45–48.
8. Zohidov KK Neuroendocrine regulation and psychovegetative syndromes . Tashkent: TMA, 2021.
9. Kilichev SA, Abdurakhmonov IR Clinical and immunometabolic efficacy of "Kretamin" in patients with neurodegenerative syndromes. Neurology and Psychiatry , 2023; 2(5): 38–44.
10. Azizova GA Antioxidant protection in neurodegeneration: pharmacological correction strategies. Modern Problems of Science and Education , 2021; 1: 56–59.
11. Cummings JL, Mega MS Neuropsychiatry and Behavioral Neuroscience . Oxford University Press, 2018.
12. Abdurakhimova NK Application of metabolically active preparations in complex treatment of cerebral atherosclerosis. Journal of Clinical Pharmacology , 2022; 3: 19–23.
13. Jumaeva NS Use of combined adaptogenic complexes in psychosomatic dysfunctions. Medical Science and Innovation , 2023; 7(4): 71–74.
14. Karimov BR The use of creatine in cerebral circulation disorders. Innovations in Medicine , 2024; 2: 27–32.
15. Bechtereva NP Brain and psyche: neurophysiological research . St. Petersburg: Nauka, 2019.
16. Khoshimov RS Clinic of Nervous Diseases and Pharmacotherapy . Tashkent: Medicine, 2022.
17. WHO. Depression and Other Common Mental Disorders. Global Health Estimates. Geneva, 2017.
18. Azizova MM Antistress effects of metabolic agents in experimental neurosis. Central Asian Medical Journal , 2022; 5: 82–85.
19. Sarimsakov MA Bioregulators and their psychotropic effects . Tashkent: FAN, 2023.